John has served as chairman of our board of directors since March 2015. He is a recognized leader in the biopharmaceutical industry with more than 30 years of experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone, and Pfizer, Inc. He currently serves as a member of the board of directors of AVEO Oncology, Melinta Therapeutics, Inc., Histogenics Corporation and Portola Pharmaceuticals, Inc. John previously served on the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.
John holds a BS from the East Stroudsburg University of Pennsylvania.
Richard has served as a member of our board of directors since March 2015. He currently serves as chief business officer, chief financial officer and as a member of the board of directors of Rapid Micro BioSystems, Inc. Since 2005, he has served as a partner of Quaker Partners Management, LP, a healthcare investment firm, which he initially joined in 2003. Richard is also on the board of directors of Tarsa Therapeutics. Richard also serves on the public policy committee for Pennsylvania Bio and is an adjunct faculty member at Lehigh University. He previously served on the board of directors of Insmed; Transave, Inc.; NuPathe, Inc.; TargetRx, Inc.; Precision Therapeutics, Inc.; Transport Pharmaceuticals, Inc.; Corridor Pharmaceuticals; Rapid Micro Biosystems, Inc; Celator Pharmaceuticals, Inc. Richard has held positions in sales, marketing and worldwide business development at GlaxoSmithKline and served as investment manager at S.R. One. He practiced as a certified public accountant for 6 years at public accounting firms, including KPMG.
Richard holds an MBA with honors and a Certificate Degree in the Graduate Program in Health Administration and Policy from University of Chicago and a BA in accounting from Franklin and Marshall College.
Garheng is founder and managing partner of HealthQuest Capital and has served as a member of our board of directors since September 2015. He brings over 20 years of clinical, technical, and business experience in creating and building high-growth and innovation-based healthcare businesses. He currently serves on the board of directors of Alimera Sciences, Castle Biosciences, Cempra, Duke University Medical Center, First Aid Shot Therapy, Histogenics, Laboratory Corporation of America, Trice Medical, and VirMedica. He previously served on the board of directors of Applied Genetic Technology Corp., Proteon, TransEnterix, Calibra Medical (acquired by J&J), Cellective (acquired by AstraZeneca), Serenex (acquired by Pfizer), NovaMin (acquired by GSK), Salveo Specialty Pharmacy (acquired by Catamaran), SARCode (acquired by Shire), and numerous industry groups. Garheng’s early career included positions at GlaxoSmithKline, McKinsey, and TherOx before he started his investing career.
Garheng earned his MD, PhD, and MBA from Duke University and received 2 undergraduate degrees in chemical engineering and biological sciences from Stanford University.
Matt has served as president and chief executive officer since August 2014 and as director on the board since September 2015. He brings more than 20 years of experience in the pharmaceutical industry. Previously he served as chief commercial officer of Insmed and senior vice president, head of global commercial operations, at Shire Pharmaceuticals. Prior, he held senior positions at Bristol-Myers Squibb and Johnson & Johnson. Matt was previously a member of the board of directors at Mast Therapeutics, Inc., and now currently serves on the board of directors of Savara Pharmaceuticals, and is a volunteer board member of the Pennington School in Pennington, New Jersey.
Matt has an MBA and BS degree from Central Michigan University and earned his JD from Michigan State University College of Law.
Jeff currently serves as chief medical officer and executive vice president of research and development at Horizon Pharma plc, and has served as a member of our board of directors since October 2016. He brings more than 25 years of research, clinical development, regulatory and commercialization experience within the biopharmaceutical industry. He is a member of a number of professional societies, a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine, and also serves on the Board of Advisors of the Center for Information and Study on Clinical Research Participation (CISCRP). He previously held senior leadership positions at IDM Pharma, Takeda Global Research and Development, NeoPharm, Searle/Pharmacia, Bristol-Myers Squibb. He is a past president of the Drug Information Association (DIA) and serves as DIA liaison to the FDA Clinical Trial Transformation Initiative (CTTI).
Jeff earned his M.D. from the Rosalind Franklin University of Medicine and Science/The Chicago Medical School. He completed internship, residency, and chief medical residency at Northwestern University Feinberg School of Medicine, where he currently serves as an adjunct assistant professor, and a fellowship program at the University of California San Francisco. He received a B.A. in Biology from Lake Forest College.
Mårten has served as a member of our board of directors since December 2014. Since April 2010, he has served as a partner of HealthCap VI LP, a venture capital firm investing in life science companies. Prior to HealthCap, he served as director at Merck Serono SA, a biopharmaceutical company. Mårten currently serves on the board of directors of Wilson Therapeutics AB, Altimmune Inc., and BioClin Therapeutics Inc. He previously served on the board of directors of Ultragenyx Inc. and FerroKin Biosciences.
Mårten holds an MD and a PhD in clinical chemistry and a BSc in business administration, all from Lund University.
Hilde has served as a member of our board of directors since January 2014. She is currently chief executive officer at Staten Biotechnology, an early-stage company developing a human monoclonal antibody with a unique approach toward neutralizing apoC3, a key molecule in dyslipidemia management. She also serves as chief operations officer and co-founder of NorthSea Therapeutics, a late-stage biopharmaceutical company with the lead candidate targeting NASH. Prior to joining Staten Biotechnology and NorthSea Therapeutics, Hilde served as head of strategic innovation management in the Nutrition and Health Division (EN), BASF, as well as head of global Omega-3 innovation management and head of investor relations for Pronova BioPharma. She is on the board of directors and acts as head of the Audit Committee of Nordic Nanovector ASA and director of PCI Biotech AS. She previously served as a member of the board of directors of Algeta ASA, Weifa AS, Invent2 AS, Alertis AS, Clavis Pharma ASA, and Biotech Pharmacon ASA.
Hilde holds a Ph.D. in medical biochemistry from the University of Oslo.
© 2018 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MACRILEN™ is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V13 01/2018